Lactobacillus reuteri SD2112

Lactobacillus reuteri SD2112 is a specific probiotic strain that produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound. Its primary mechanism involves suppressing Helicobacter pylori urease activity and reducing bacterial colonization in the gastric mucosa.

Origin & History

Lactobacillus reuteri SD2112 (also designated ATCC 55730) is a specific probiotic bacterial strain originally isolated from human sources and used in gastrointestinal health applications including tablets like Reuterina. It is a Gram-positive anaerobic bacterium propagated in microbial culture media rather than extracted from plants, capable of producing antimicrobial compounds including reuterin.

Historical & Cultural Context

No historical or traditional medicine use was identified for L. reuteri SD2112. It is a modern probiotic strain developed for clinical and food applications since the 1980s-2000s, without roots in traditional medicine systems.

Health Benefits

• Reduces H. pylori infection burden by 69.7% as measured by urea breath test values (moderate evidence from RCT, PMID: 17695792)
• Suppresses H. pylori urease activity with sustained effects post-treatment (moderate evidence from clinical trial)
• Reduces antibiotic-associated side effects when combined with H. pylori therapy in children (moderate evidence from 2006 RCT)
• Decreases Gastrointestinal Symptom Rating Scale scores in pediatric patients (moderate evidence)
• Produces reuterin, an antimicrobial compound that inhibits pathogenic bacteria (preliminary evidence from in-vitro studies)

How It Works

Lactobacillus reuteri SD2112 produces reuterin (3-hydroxypropionaldehyde) via glycerol fermentation, which disrupts H. pylori cell membranes and inhibits the urease enzyme responsible for ammonia production and gastric mucosal damage. The strain also competes with H. pylori for adhesion sites on gastric epithelial cells by binding to sialyl-Lewis x and Lewis b antigens. Additionally, it modulates host innate immunity by stimulating Toll-like receptor 2 (TLR2) signaling, promoting anti-inflammatory cytokine profiles that reduce gastric mucosal inflammation.

Scientific Research

A key randomized controlled trial (PMID: 17695792) tested L. reuteri SD2112 tablets in H. pylori-positive adults using a crossover design (n=20-30 per group) over 8 weeks, demonstrating significant reduction in urea breath test values. A 2006 RCT in H. pylori-positive children showed the strain reduced antibiotic side effects when combined with sequential therapy.

Clinical Summary

A randomized controlled trial (PMID: 17695792) demonstrated that L. reuteri SD2112 supplementation reduced H. pylori infection burden by 69.7% as measured by urea breath test delta-over-baseline values. The same trial reported sustained suppression of urease activity following the treatment period, suggesting durable colonization resistance. Evidence for reduction of antibiotic-associated gastrointestinal side effects comes from clinical trial data, though sample sizes in individual studies are generally modest, placing the overall evidence at a moderate level. Larger, multi-center RCTs are needed to confirm optimal dosing and long-term efficacy.

Nutritional Profile

Lactobacillus reuteri SD2112 is a probiotic bacterial strain with negligible macronutrient contribution at typical supplemental doses (10^8–10^10 CFU/day). Primary bioactive components include: (1) Reuterin (3-hydroxypropionaldehyde, 3-HPA) — an antimicrobial compound produced during glycerol fermentation, active at concentrations of 15–30 mM in vitro, inhibits competing pathogens including H. pylori; (2) Reutericyclin — a tetramic acid antibiotic unique to L. reuteri with broad-spectrum antimicrobial activity; (3) Cobalamin (Vitamin B12) — L. reuteri is among rare gut bacteria capable of de novo cobalamin biosynthesis, contributing endogenous B12 to the host intestinal environment, though exact luminal concentrations from SD2112 specifically are not well-quantified in human studies; (4) Folate — produced in modest quantities during fermentation; (5) Short-chain fatty acids (SCFAs), particularly acetate and small amounts of propionate, generated as metabolic byproducts; (6) Exopolysaccharides (EPS) — cell-surface glycans that mediate mucoadhesion and immunomodulation, enhancing colonization efficiency in the gastric mucosa relevant to H. pylori interaction; (7) Surface-layer proteins (SlpA) facilitating epithelial adhesion. Bioavailability note: SD2112 demonstrates acid and bile tolerance superior to many Lactobacillus strains, with documented survival through gastric transit at doses ≥10^8 CFU; transient colonization is typical, requiring continuous dosing for sustained effect. Caloric contribution is negligible (<1 kcal per standard dose).

Preparation & Dosage

Clinical trials used L. reuteri SD2112 in tablet form (Reuterina) for 4-8 weeks, though exact CFU counts were not specified in available research. Related L. reuteri strains typically use 10^8-10^9 CFU/day in powder or suspension forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, prebiotics, glycerol (reuterin substrate), digestive enzymes, zinc carnosine

Safety & Interactions

Lactobacillus reuteri SD2112 is generally recognized as safe (GRAS) and well-tolerated in healthy adults, with the most commonly reported adverse effects being transient bloating and mild gastrointestinal discomfort. Immunocompromised individuals, critically ill patients, and those with central venous catheters should use caution due to rare theoretical risk of bacteremia associated with viable probiotic strains. Concurrent use with systemic antibiotics may reduce viability of the strain; timing supplementation at least 2 hours apart from antibiotic doses is commonly advised. Safety data in pregnancy is limited and consultation with a healthcare provider is recommended before use.